Azilect® Slows The Progression Of Parkinson's Disease In Clinical Trial

H. Lundbeck Lundbeck's partner Teva Pharmaceutical Industries Ltd. has today announced the successful completion of ADAGIO, the phase III trial designed to demonstrate that Azilect® 1 mg tablets can slow down the progression of Parkinson's disease. In the trial, the currently marketed Azilect® 1 mg tablets met all three primary end points, as well as the secondary and additional end points, all with statistical significance. The study also confirmed the safety and tolerability of Azilect®.

Lundbeck markets Azilect® in Europe. In the three major European markets, the United Kingdom, Germany and France, Teva and Lundbeck co-promote Azilect®.

About the Study ADAGIO is a randomized, multi-center, double-blind, placebo-controlled, parallel-group study prospectively examining rasagiline's potential disease-modifying effects in 1,176 patients with early, untreated Parkinson's disease. Patients from 129 centers in 14 countries were randomized to early-start treatment (72 weeks rasagiline 1 or 2 mg once daily) or delayed-start treatment (36 weeks placebo followed by 36 weeks rasagiline 1 or 2 mg once daily [active treatment phase]). The primary analyses of the trial were based on change in total UPDRS (Unified Parkinson's Disease Rating Scale).

The content of this release will have no influence on the Lundbeck Group's financial result for 2008. Lundbeck expects the good results to have a significant positive impact on Azilect® sales in Europe in the coming years.

Lundbeck contacts

Investors: Media:

Jacob Tolstrup Jens Harder Højbjerg Director Media Relations Manager +45 36 43 30 79 +45 36 43 28 33

Palle Holm Olesen Head of Investor Relations +45 36 43 24 26

Stock Exchange Release No 348 - 16 June 2008

About Lundbeck H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. In 2007, the company's revenue was DKK 11 billion (approximately EUR 1.6 billion or USD 2.0 billion). The number of employees is approx. 5,300 globally. For more information, please visit www.lundbeck.com.

H. Lundbeck

http://www.lundbeck.com

ISIN: DK0010287234

Stock Identifier: XCSE.LUN